Cargando…
Use of bone‐modifying agents and clinical outcomes in older adults with multiple myeloma
BACKGROUND: Guidelines recommend bone‐modifying agents (BMAs) for all patients initiating treatment for myeloma. We examined adherence to this recommendation, and BMA effectiveness in the era of bortezomib/lenalidomide‐based therapy among Medicare beneficiaries. METHODS: From the linked Surveillance...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853813/ https://www.ncbi.nlm.nih.gov/pubmed/31566898 http://dx.doi.org/10.1002/cam4.2591 |